


**Nasopharyngeal Cancer (C11): 2000-2007**  
**Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries**

| Sex   |                              | Bulgaria | Poland | Slovakia | Scotland | Portugal | Croatia | Czech Republic | England | Austria | European average | Italy | France | Denmark | Norway | Ireland | Germany | Belgium | The Netherlands | Spain | Northern Ireland | Switzerland | Wales | Finland | Latvia | Slovenia | Malta | Sweden | Lithuania | Estonia | Iceland |
|-------|------------------------------|----------|--------|----------|----------|----------|---------|----------------|---------|---------|------------------|-------|--------|---------|--------|---------|---------|---------|-----------------|-------|------------------|-------------|-------|---------|--------|----------|-------|--------|-----------|---------|---------|
| Men   | 5-Year Relative Survival (%) | 27.14    | 27.95  | 35.06    | 40.13    | 41.26    | 43.30   | 46.35          | 46.96   | 47.16   | 47.17            | 47.24 | 49.16  | 49.87   | 50.15  | 50.28   | 50.86   | 52.66   | 53.22           | 53.53 | 60.84            | 75.45       |       |         |        |          |       |        |           |         |         |
|       | 95% LCL                      | 22.36    | 20.18  | 27.84    | 30.62    | 35.01    | 33.95   | 39.93          | 43.35   | 38.65   | 44.98            | 43.30 | 40.80  | 40.00   | 37.82  | 38.68   | 44.79   | 43.65   | 48.12           | 45.42 | 45.02            | 62.58       |       |         |        |          |       |        |           |         |         |
|       | 95% UCL                      | 32.93    | 38.70  | 44.16    | 52.59    | 48.62    | 55.24   | 53.81          | 50.87   | 57.55   | 49.47            | 51.54 | 59.23  | 62.16   | 66.49  | 65.37   | 57.75   | 63.53   | 58.87           | 63.10 | 82.22            | 90.97       |       |         |        |          |       |        |           |         |         |
| Women | 5-Year Relative Survival (%) | 33.99    | 41.14  | 44.83    | 70.79    | 56.28    |         | 43.67          | 50.45   | 63.53   | 54.73            | 57.05 | 59.09  | 48.52   | 52.26  |         | 54.35   | 60.73   | 54.19           |       |                  |             |       |         | 33.50  |          |       | 57.47  |           |         |         |
|       | 95% LCL                      | 27.27    | 31.08  | 32.35    | 58.72    | 47.39    |         | 33.94          | 45.82   | 52.71   | 51.68            | 51.07 | 46.54  | 36.42   | 44.00  |         | 46.54   | 48.08   | 46.20           |       |                  |             |       | 20.70   |        |          | 44.29 |        |           |         |         |
|       | 95% UCL                      | 42.35    | 54.46  | 62.13    | 85.35    | 66.83    |         | 56.19          | 55.54   | 76.58   | 57.95            | 63.72 | 75.01  | 64.64   | 62.06  |         | 63.47   | 76.69   | 63.57           |       |                  |             |       | 54.24   |        |          | 74.57 |        |           |         |         |



All invasive, primary, malignant neoplasms except non-melanoma skin cancer were eligible for inclusion.  
 Data consists of both observed and predicted 5-year relative survival.  
 Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.  
 For some European countries data is not available for one or both sexes.  
 95% LCL and 95% UCL are the 95% lower and upper confidence limits around the five-year relative survival.  
 Source: [cruk.org/cancerstats](http://cruk.org/cancerstats)  
 You are welcome to reuse this Cancer Research UK statistics content for your own work.  
 Credit us as authors by referencing Cancer Research UK as the primary source.  
 Suggested style: Cancer Research UK, full URL of the page, Accessed [month] [year].

